Please use this identifier to cite or link to this item:
|Title:||Adjunctive Docosahexaenoic Acid in Residual Symptoms of Depression and Anxiety.||Austin Authors:||Piperoglou, Michael;Hopwood, Malcolm;Norman, Trevor R||Affiliation:||From the Epworth Hospital, Camberwell.
Department of Psychiatry, University of Melbourne, Melbourne.
Psychiatry (University of Melbourne)
|Issue Date:||Nov-2023||Date:||2023||Publication information:||Journal of Clinical Psychopharmacology 2023-11; 43(6)||Abstract:||The aim of the study is to examine the efficacy of omega-3 fatty acid as an adjunct to ongoing pharmacological treatments in patients with residual symptoms of depression and anxiety. This randomized, double-blind, placebo-controlled, cross-over trial was conducted at a single private practice site. Participants were drawn from patients attending the practice.Patients meeting criteria had a 4-week run-in period where they continued to receive their prescribed medications and omega-3 supplements. Depression and anxiety ratings were assessed at recruitment and completion of the run-in phase. Patients were randomized to receive an omega-3 supplement (Neurospark) or placebo once daily for 8 weeks then crossed over to the alternative treatment. At the end of the double-blind, cross-over phase patients received the supplement and were assessed after a 4-week run-out phase.Depression and anxiety symptoms were assessed using the Hamilton scales. Efficacy of treatment was assessed using a linear mixed model analysis with time, order of treatment, diagnosis, and their interaction as factors. Depression and anxiety scales were analyzed as independent measures. The study enrolled 47 patients (mean [SD] age, 46.1 [11.2] years; [59.6%] male). Depression scores did not significantly change across assessments ( P > 0.1); there was no effect of order of treatment ( P > 0.1) or an interaction between time, order of treatment, and psychiatric diagnosis ( P > 0.1). Anxiety scores were similarly unchanged across treatment visits and order of treatment, and there was no interaction between time, order of treatment, and psychiatric diagnosis. Omega-3 fatty acid supplementation did not significantly alter residual symptoms in this group of patients.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/34101||DOI:||10.1097/JCP.0000000000001767||ORCID:||0000000334011763
|Journal:||Journal of Clinical Psychopharmacology||PubMed URL:||37878482||ISSN:||1533-712X||Type:||Journal Article|
|Appears in Collections:||Journal articles|
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.